IRVING, Texas / Dec 30, 2024 / Business Wire / McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025.
The live webcast for each event will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings release, financial tables and slide presentation.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
| Last Trade: | US$750.13 |
| Daily Change: | 8.84 1.19 |
| Daily Volume: | 630,835 |
| Market Cap: | US$93.300B |
August 06, 2025 February 05, 2025 February 04, 2025 November 06, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
